US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

Healthcare companies are navigating a challenging environment as policy uncertainty and competitive pressures weigh on the ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Arvinas, Inc. (NASDAQ: ARVN) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Voyager struggles with a negative enterprise value, financial risks, and limited catalysts in a competitive Alzheimer's ...

Ireland’s economic data was always going to be a bit special at the start of this year. But Thursday’s figures were ...

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 ...